$5.45
+0.12(2.25%)
Mkt Cap $198M
$1.10
$9.26
52-Week Range
At a Glance
AI-generatedImmuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024.
8-K
Immuneering Corporation announced Q4 and full-year 2025 financial results, reporting 64% overall survival at 12 months in its Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, cash of $217 million extending runway into 2029, and alignment with FDA/EMA on Phase 3 trial design with first patient dosing mid-2026.$198M
Market Cap
—
Revenue
-$46M
Net Income
Employees54
Fundamentals
How The Business Makes Money
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001790340
ISINUS45254E1073
CUSIP45254E107
Phone617 500 8080
Address245 Main Street, Cambridge, MA, 02142, US
SEC EDGAR